What's new

Human medicines European public assessment report (EPAR): Revinty Ellipta, fluticasone furoate,vilanterol, Date of authorisation: 02/05/2014, Revision: 25, Status: Authorised

Human medicines European public assessment report (EPAR): Revinty Ellipta, fluticasone furoate,vilanterol, Date of authorisation: 02/05/2014, Revision: 25, Status: Authorised

Mar 14, 2025 - 16:11
 0
Human medicines European public assessment report (EPAR): Revinty Ellipta, fluticasone furoate,vilanterol, Date of authorisation: 02/05/2014, Revision: 25, Status: Authorised
Human medicines European public assessment report (EPAR): Revinty Ellipta, fluticasone furoate,vilanterol, Date of authorisation: 02/05/2014, Revision: 25, Status: Authorised
Read More

Tags:

Previous Article

Brad Pitt's 'F1' Has A Nonsensical Plot, But I Can't Look Away From The Trailer

Next Article

MISO overstates transmission plan benefits by excluding Invenergy project: marke...

Related Posts

Mandatory use of ISO/ICH E2B(R3) individual case safety reporting in the EU: hands-on training course using the EudraVigilance system, Online, European Medicines Agency, Amsterdam, the Netherlands, from 12 May 2025 to 16 May 2025

Mandatory use of ISO/ICH E2B(R3) individual case safety...

Feb 14, 2025  0

Human medicines European public assessment report (EPAR): Ituxredi, rituximab, Date of authorisation: 19/09/2024, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 10, 2025  0

Orphan designation: Humanised IgG4 monoclonal antibody against C1q Treatment of Guillain-Barré syndrome, 10/02/2025 Positive

Orphan designation: Humanised IgG4 monoclonal antibody ...

Mar 12, 2025  0